Compared with non‐cancerous tissues, PC expression is greatly enhanced in patients with non‐small cell lung cancer (NSCLC) and invasive breast cancer (BCA).[9] In early stages of NSCLC, growth inhibition by PC knockdown is accompanied by disrupted TCA activity and biosynthesis.[10] In particular, BCA accounts for the highest frequency of PC amplification according to The Cancer Genome Atlas (TCGA). Here, BLNK is linked to non-small cell lung carcinoma.